Published in J Virol on March 21, 2007
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 2.02
Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity (2009) 1.94
Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78
Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol (2010) 1.69
Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol (2008) 1.63
Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol (2008) 1.22
Emerging concepts in CD8(+) T regulatory cells. Curr Opin Immunol (2008) 1.09
T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis (2015) 1.09
CD8+ Tregs in lupus, autoimmunity, and beyond. Autoimmun Rev (2010) 1.04
Suppressive CD8+ T cells arise in the absence of CD4 help and compromise control of persistent virus. J Immunol (2011) 1.02
T cell exhaustion during persistent viral infections. Virology (2015) 1.00
T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg Microbes Infect (2013) 1.00
Regulatory T cells in viral hepatitis. World J Gastroenterol (2007) 0.99
Presence of suppressor HIV-specific CD8+ T cells is associated with increased PD-1 expression on effector CD8+ T cells. J Immunol (2008) 0.98
T cells with regulatory activity in hepatitis C virus infection: what we know and what we don't. J Leukoc Biol (2008) 0.93
Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol (2008) 0.92
Innate and Adaptive Immune Regulation During Chronic Viral Infections. Annu Rev Virol (2015) 0.89
Negative regulation of type I IFN expression by OASL1 permits chronic viral infection and CD8⁺ T-cell exhaustion. PLoS Pathog (2013) 0.88
Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol J (2009) 0.87
CD4+ primary T cells expressing HCV-core protein upregulate Foxp3 and IL-10, suppressing CD4 and CD8 T cells. PLoS One (2014) 0.87
Adaptive immune response during hepatitis C virus infection. World J Gastroenterol (2014) 0.85
Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy. PLoS One (2012) 0.83
TGF-beta and IL-10 production by HIV-specific CD8+ T cells is regulated by CTLA-4 signaling on CD4+ T cells. PLoS One (2009) 0.82
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discov (2016) 0.82
Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis. Hepatology (2012) 0.80
Characterization of antigenic variants of hepatitis C virus in immune evasion. Virol J (2011) 0.79
Determinants of in vitro expansion of different human virus-specific FoxP3+ regulatory CD8+ T cells in chronic hepatitis C virus infection. J Gen Virol (2009) 0.79
Minimal effect of CD103 expression on the control of a chronic antiviral immune response. Viral Immunol (2010) 0.76
Molecular and Cellular Characterization of Human CD8 T Suppressor Cells. Front Immunol (2016) 0.76
Acute hepatitis C virus infection in a nurse trainee following a needlestick injury. World J Gastroenterol (2013) 0.75
Regulatory T Cells in Hepatitis B and C Virus Infections. Immune Netw (2016) 0.75
Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol (2015) 0.75
CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol (2002) 12.73
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
Natural versus adaptive regulatory T cells. Nat Rev Immunol (2003) 8.74
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
Analysis of a successful immune response against hepatitis C virus. Immunity (1999) 6.31
Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology (1999) 5.79
Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med (2000) 4.98
Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis (2001) 4.72
Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet (1995) 4.71
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med (2003) 4.20
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest (1996) 4.10
Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology (1999) 3.73
CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol (2002) 3.41
Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A (1999) 3.30
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18
Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol (1992) 3.13
Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol (2005) 3.00
Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis (2000) 2.98
T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol (2005) 2.58
Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology (2003) 2.45
Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest (2004) 2.25
Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol (2005) 2.14
Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells. J Immunol (2005) 2.11
Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med (1993) 1.90
Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med (2004) 1.89
Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol (2004) 1.75
Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions. Nature (1988) 1.71
CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis (2002) 1.69
Enhanced peripheral T-cell apoptosis in chronic hepatitis C virus infection: association with liver disease severity. J Hepatol (2001) 1.61
Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology (2003) 1.52
Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol (2002) 1.40
Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol (2001) 1.36
Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol (2003) 1.35
Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol (2004) 1.32
Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol (2005) 1.27
The HCV core protein acts as a positive regulator of fas-mediated apoptosis in a human lymphoblastoid T cell line. Virology (2000) 1.23
Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology (2004) 1.19
Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS (2000) 1.17
HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. AIDS (2002) 1.15
Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis (2004) 1.12
Viral escape and T cell exhaustion in hepatitis C virus infection analysed using Class I peptide tetramers. Immunol Lett (2003) 1.10
Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. AIDS (2002) 1.01
Apoptosis of activated CD4+ and CD8+ T cells is enhanced by co-culture with hepatocytes expressing hepatitis C virus (HCV) structural proteins through FasL induction. Virology (2005) 0.95
CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection. J Infect Dis (2005) 0.94
Possible role of cytotoxic T cells in acute liver injury in hepatitis C virus cDNA transgenic mice mediated by Cre/loxP system. J Med Virol (2000) 0.91
Studies of human antiviral CD8+ lymphocytes using class I peptide tetramers. Rev Med Virol (2001) 0.91
Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS (2005) 0.89
Non-antigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. Ann N Y Acad Sci (2005) 0.83
Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection. AIDS (2004) 0.82
Effect of exposure to injection drugs or alcohol on antigen-specific immune responses in HIV and hepatitis C virus coinfection. J Infect Dis (2007) 0.79
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86
Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity (2012) 2.80
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol (2007) 2.47
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis (2005) 2.06
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci U S A (2007) 1.84
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res (2007) 1.84
End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood (2002) 1.73
Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr (2004) 1.65
GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis (2006) 1.64
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology (2004) 1.51
The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology (2006) 1.49
To be or not to be NKT: natural killer T cells in the liver. Hepatology (2004) 1.49
The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner. Immunology (2006) 1.44
CD1d ligation on human monocytes directly signals rapid NF-kappaB activation and production of bioactive IL-12. Proc Natl Acad Sci U S A (2005) 1.40
Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer (2005) 1.39
Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology (2006) 1.38
HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis (2011) 1.37
Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology (2004) 1.36
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology (2006) 1.32
Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology (2006) 1.30
Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol (2004) 1.27
Multiple pseudotumors in IgG4-associated multifocal systemic fibrosis. Ann Intern Med (2004) 1.27
Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol (2004) 1.25
HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS (2011) 1.23
The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr (2007) 1.22
MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood (2002) 1.21
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis (2006) 1.19
Impaired cell surface expression of human CD1d by the formation of an HIV-1 Nef/CD1d complex. Virology (2005) 1.19
Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology (2004) 1.19
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One (2012) 1.19
The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis (2011) 1.17
Acute hepatitis C virus infection: a chronic problem. Hepatology (2008) 1.15
Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J Infect Dis (2004) 1.14
Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis (2004) 1.12
Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy. Gastrointest Endosc (2002) 1.11
Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis (2004) 1.11
HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood (2004) 1.08
HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. Hepatology (2006) 1.07
Clinical application of polymerase chain reaction to diagnose Clostridium difficile in hospitalized patients with diarrhea. Clin Gastroenterol Hepatol (2004) 1.07
Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. J Clin Invest (2010) 1.06
Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci (2010) 1.06
CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci U S A (2003) 1.06
First things first: balancing hepatitis C and human immunodeficiency virus. Clin Infect Dis (2003) 1.06
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology (2005) 1.05
Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells. J Immunol (2013) 1.05
Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis (2011) 1.04
Health values of patients coinfected with HIV/hepatitis C: are two viruses worse than one? Med Care (2006) 1.02
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res (2008) 1.01
Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis (2013) 1.00
Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis (2004) 0.98
Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol (2007) 0.98
Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis. Vaccine (2005) 0.98
Hepatitis C virus coinfection and superinfection. J Infect Dis (2007) 0.97
CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Exp Dermatol (2005) 0.96
Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide. Cancer Res (2006) 0.96
The A2aR adenosine receptor controls cytokine production in iNKT cells. Eur J Immunol (2010) 0.96
Apoptosis of activated CD4+ and CD8+ T cells is enhanced by co-culture with hepatocytes expressing hepatitis C virus (HCV) structural proteins through FasL induction. Virology (2005) 0.95
The changing epidemiology of liver disease in HIV patients. AIDS Rev (2013) 0.94
CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection. J Infect Dis (2005) 0.94
Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline. Curr HIV/AIDS Rep (2012) 0.94
Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide. PLoS One (2010) 0.94
HIV and liver disease forum: conference proceedings. Hepatology (2007) 0.93
Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin Infect Dis (2012) 0.93
Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. Am J Public Health (2012) 0.93
NKT-cell-based immunotherapies in clinical trials. Clin Immunol (2011) 0.93
Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol (2008) 0.92
CD1d-based combination therapy eradicates established tumors in mice. J Immunol (2009) 0.92
Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. J Immunol (2008) 0.92
Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother (2003) 0.92
CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo. J Virol (2006) 0.91
Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity. J Immunol Methods (2007) 0.90
Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo. J Immunol (2009) 0.90
Gestation stage-dependent mechanisms of invariant natural killer T cell-mediated pregnancy loss. Proc Natl Acad Sci U S A (2006) 0.90
Invariant natural killer T cells and immunotherapy of cancer. Clin Immunol (2008) 0.90
IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS One (2011) 0.89
Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C. Liver Int (2006) 0.89
Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS (2005) 0.89
Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro. J Immunol (2013) 0.89
Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia. Clin Gastroenterol Hepatol (2013) 0.88
Hepatitis E virus antibodies in patients with chronic liver disease. Emerg Infect Dis (2009) 0.88
Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women. J Antimicrob Chemother (2009) 0.88
Natural killer T cell-based cancer immunotherapy. Clin Cancer Res (2006) 0.88